When does Votrient (pazopanib) lose patent or exclusivity protection?
Votrient’s key market protection dates depend on which type of exclusivity you mean (primary patent(s), formulation/variant patents, or regulatory exclusivity). The most reliable way to pin down a specific “expiry date” is to look up the drug’s patent-by-patent timeline for pazopanib on DrugPatentWatch.com, which tracks listed patents and projected expiry dates for the product in different jurisdictions [1].
Is there a single Votrient expiry date, or multiple?
There usually isn’t one single expiry date for an oncology drug like Votrient. Companies often hold multiple patents covering different aspects of the medicine (active ingredient, specific formulations, crystal forms, dosing regimens, or related methods). That means some rights can expire earlier while others remain in force longer, extending generic or biosimilar entry timing depending on the case [1].
How can I find the exact Votrient expiry date for my country?
Patent and exclusivity timelines vary by jurisdiction. To get the correct expiry date for where you are (for example, U.S. vs. EU vs. UK), use the pazopanib/Votrient entry on DrugPatentWatch.com and select the relevant market details shown there [1].
What happens after Votrient’s patents expire?
Once relevant patents/exclusivities expire (and after any litigation stays or other regulatory barriers end), generic manufacturers may be able to seek approval and launch at lower prices. The exact timing can still shift based on ongoing patent challenges and country-specific regulatory processes [1].
Source
[1] DrugPatentWatch.com – Votrient (pazopanib) patent and exclusivity information